Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
John Goldberg, Maria Luisa Sulis, Julia Bender, Sima Jeha, Rebecca Gardner, Jessica Pollard, Victor Aquino, Theodore Laetsch, Naomi Winick, Cecilia Fu, Leigh Marcus, Weili Sun, Anupam Verma, Michael Burke, Phoenix Ho, Thomas Manley, Rajen Mody, Wendy Tcheng, Blythe Thomson, Julie Park, Richard Sposto, Yoav Messinger, Nobuko Hijiya, Paul Gaynon & Julio Barredo. (2020) A phase I study of panobinostat in children with relapsed and refractory hematologic malignancies. Pediatric Hematology and Oncology 37:6, pages 465-474.
Read now
Read now
JungIn Um, Ji-Hyung Lee, Da-Woon Jung & Darren R. Williams. (2018) Re-education begins at home: an overview of the discovery of in vivo-active small molecule modulators of endogenous stem cells. Expert Opinion on Drug Discovery 13:4, pages 307-326.
Read now
Read now
Fortunato Morabito, Maria Teresa Voso, Stefan Hohaus, Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lorenzo Iovino, Edoardo Benedetti, Francesco Lo-Coco & Sara Galimberti. (2016) Panobinostat for the treatment of acute myelogenous leukemia. Expert Opinion on Investigational Drugs 25:9, pages 1117-1131.
Read now
Read now
Rajshekhar Chakraborty, Prashant Kapoor, Stephen M Ansell & Morie A Gertz. (2015) Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. Expert Review of Anticancer Therapy 15:10, pages 1143-1156.
Read now
Read now
Rajshekhar Chakraborty, Stephen A Ansell, Prashant Kapoor & Morie A Gertz. (2015) Phase II clinical trials for Waldenstrom’s macroglobulinemia. Expert Opinion on Orphan Drugs 3:5, pages 537-547.
Read now
Read now
Michael Dickinson & Henry Miles Prince. (2014) Emerging drugs for T-cell lymphoma. Expert Opinion on Emerging Drugs 19:2, pages 201-213.
Read now
Read now
Emmanuella Guenova, Wolfram Hoetzenecker, Sima Rozati, Mitchell P Levesque, Reinhard Dummer & Antonio Cozzio. (2014) Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. Expert Opinion on Investigational Drugs 23:4, pages 457-467.
Read now
Read now
Articles from other publishers (30)
Yun Deng, Qian Cheng & Jing He. (2023) HDAC inhibitors: Promising agents for leukemia treatment. Biochemical and Biophysical Research Communications 680, pages 61-72.
Crossref
Crossref
Haodong Ding, Yuwei Li, Maoxin Fang, Jiaojiao Chen, Lipin Liu, Zhigang Lu, Jia Hou & Min Luo. (2023) Epigenetic activation of the TUSC3 gene as a potential therapy for XMEN disease. Journal of Allergy and Clinical Immunology 151:6, pages 1622-1633.e10.
Crossref
Crossref
Dilipkumar Pal, Khushboo Raj, Shyam Sundar Nandi, Surajit Sinha, Abhishek Mishra, Arijit Mondal, Ricardo Lagoa, Jack T. Burcher & Anupam Bishayee. (2023) Potential of Synthetic and Natural Compounds as Novel Histone Deacetylase Inhibitors for the Treatment of Hematological Malignancies. Cancers 15:10, pages 2808.
Crossref
Crossref
Zhe Peng, Quanfeng Zhao, Xiaoyan Tian, Tiantian Lei, Rongfeng Xiang, Lin Chen & Yang Yang. (2022) Discovery of Potent and Isoform‐selective Histone Deacetylase Inhibitors Using Structure‐based Virtual Screening and Biological Evaluation. Molecular Informatics, pages 2100295.
Crossref
Crossref
Xiaoxia Liang, Pan Wu, Qian Yang, Yunyu Xie, Changliang He, Lizi Yin, Zhongqiong Yin, Guizhou Yue, Yuanfeng Zou, Lixia Li, Xu Song, Cheng Lv, Wei Zhang & Bo Jing. (2021) An update of new small-molecule anticancer drugs approved from 2015 to 2020. European Journal of Medicinal Chemistry 220, pages 113473.
Crossref
Crossref
Lia PerezHugo Fernandez, Mohamed Kharfan-Dabaja, Farhad KhimaniBrian BettsAsmita MishraErnesto AyalaFrederick L. LockeLeonel Ochoa-BayonaMichael NiederJoseph Pidala, Alex Achille, John Powers, Eva Sahakian, Ram Thapa, Xuefeng Wang & Claudio Anasetti. (2021) A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Advances 5:13, pages 2740-2750.
Crossref
Crossref
Omeima Abdullah, Ziad Omran, Salman Hosawi, Ali Hamiche, Christian Bronner & Mahmoud Alhosin. (2021) Thymoquinone Is a Multitarget Single Epidrug That Inhibits the UHRF1 Protein Complex. Genes 12:5, pages 622.
Crossref
Crossref
Hui Zhang, Aya Laux, Kurt R. Stenmark & Cheng-Jun Hu. (2021) Mechanisms Contributing to the Dysregulation of miRNA-124 in Pulmonary Hypertension. International Journal of Molecular Sciences 22:8, pages 3852.
Crossref
Crossref
Yizhen Liu, Renhong Huang, Lianfang Liu, Yanchun Meng & Xiaojian Liu. (2019) Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape. Cell Biochemistry and Function 38:3, pages 242-248.
Crossref
Crossref
Veronika A. Myasoedova, Vasily Sukhorukov, Andrey V. Grechko, Dongwei Zhang, Elena Romanenko, Vawain Orekhov & Alexander N. Orekhov. (2019) Inhibitors of DNA Methylation and Histone Deacetylation as Epigenetically Active Drugs for Anticancer Therapy. Current Pharmaceutical Design 25:6, pages 635-641.
Crossref
Crossref
Dong Hoon Lee, Go Woon Kim & So Hee Kwon. (2019) The HDAC6‐selective inhibitor is effective against non‐Hodgkin lymphoma and synergizes with ibrutinib in follicular lymphoma. Molecular Carcinogenesis 58:6, pages 944-956.
Crossref
Crossref
Lia Perez, Hugo Fernandez, Pedro Horna, Marcie Riches, Frederick Locke, Teresa Field, John Powers, Eva Sahakian, Alejandro Villagra, Asmita Mishra, Brian Betts, Mohamed Kharfan-Dabaja, Francisca Beato, Leonel Ochoa-Bayona, Joseph Pidala & Claudio Anasetti. (2018) Phase I trial of histone deacetylase inhibitor panobinostat in addition to glucocorticoids for primary therapy of acute graft-versus-host disease. Bone Marrow Transplantation 53:11, pages 1434-1444.
Crossref
Crossref
Tingting Pan, Jiaqian Qi, Tao You, Liping Yang, Depei Wu, Yue Han & Li Zhu. (2018) Addition of histone deacetylase inhibitors does not improve prognosis in patients with myelodysplastic syndrome and acute myeloid leukemia compared with hypomethylating agents alone: A systematic review and meta-analysis of seven prospective cohort studies. Leukemia Research 71, pages 13-24.
Crossref
Crossref
Marije Bartels, Anita Govers, Roel Polak, Stephin Vervoort, Ruben van Boxtel, Cornelieke Pals, Marc Bierings, Wouter van Solinge, Toine Egberts, Edward Nieuwenhuis, Michal Mokry & Paul James Coffer. (2018) Megakaryocyte lineage development is controlled by modulation of protein acetylation. PLOS ONE 13:4, pages e0196400.
Crossref
Crossref
Qing Zhang, Yifan Dai, Zhiming Cai & Lisha Mou. (2018) HDAC Inhibitors: Novel Immunosuppressants for Allo- and Xeno- Transplantation. ChemistrySelect 3:1, pages 176-187.
Crossref
Crossref
Yukio Kobayashi, Wataru Munakata, Michinori Ogura, Toshiki Uchida, Masafumi Taniwaki, Tsutomu Kobayashi, Fumika Shimada, Masataka Yonemura, Fumiko Matsuoka, Takeshi Tajima, Kimikazu Yakushijin & Hironobu Minami. (2017) Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia. International Journal of Hematology 107:1, pages 83-91.
Crossref
Crossref
Leigh Anne Hylton Gravatt, Crystal R Leibrand, Sulay Patel & MaryPeace McRae. (2017) New Drugs in the Pipeline for the Treatment of HIV: a Review. Current Infectious Disease Reports 19:11.
Crossref
Crossref
Vanita Chopra, Luisa Quinti, Prarthana Khanna, Paolo Paganetti, Rainer Kuhn, Anne B. Young, Aleksey G. Kazantsev & Steven Hersch. (2016) LBH589, A Hydroxamic Acid-Derived HDAC Inhibitor, is Neuroprotective in Mouse Models of Huntington’s Disease. Journal of Huntington's Disease 5:4, pages 347-355.
Crossref
Crossref
Øystein Helland, Mihaela Popa, Katharina Bischof, Bjørn Tore Gjertsen, Emmet McCormack & Line Bjørge. (2016) The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLOS ONE 11:6, pages e0158208.
Crossref
Crossref
Pier Luigi Zinzani, Vijayveer Bonthapally, Dirk Huebner, Richard Lutes, Andy Chi & Stefano Pileri. (2016) Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas. Critical Reviews in Oncology/Hematology 99, pages 214-227.
Crossref
Crossref
Madeleine Duvic. (2015) Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma. Dermatologic Clinics 33:4, pages 757-764.
Crossref
Crossref
Stephen G. DaviesPeter D. KennewellAngela J. RussellPeter T. SedenRobert WestwoodGraham M. Wynne. (2015) Stemistry: The Control of Stem Cells in Situ Using Chemistry. Journal of Medicinal Chemistry 58:7, pages 2863-2894.
Crossref
Crossref
Fernando F. Corrales-Medina, Christa A. Manton, Robert Z. Orlowski & Joya Chandra. (2015) Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leukemia Research 39:3, pages 371-379.
Crossref
Crossref
Teng Ai, Yanli Xu, Li Qiu, Robert J. Geraghty & Liqiang Chen. (2014) Hydroxamic Acids Block Replication of Hepatitis C Virus. Journal of Medicinal Chemistry 58:2, pages 785-800.
Crossref
Crossref
Lu Gao, Minjie Gao, Guang Yang, Yi Tao, Yuanyuan Kong, Ruixue Yang, Xiuqin Meng, Gongwen Ai, Rong Wei, Huiqun Wu, Xiaosong Wu & Jumei Shi. (2015) Synergistic Activity of Carfilzomib and Panobinostat in Multiple Myeloma Cells via Modulation of ROS Generation and ERK1/2. BioMed Research International 2015, pages 1-9.
Crossref
Crossref
Pierfausto Seneci. 2015. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease. Chemical Modulators of Protein Misfolding and Neurodegenerative Disease
135
172
.
Sunil Sharma, Petronella O. Witteveen, Martijn P. Lolkema, Dagmar Hess, Hans Gelderblom, Syed A. Hussain, Maria G. Porro, Edward Waldron, Sue-zette Valera & Song Mu. (2014) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemotherapy and Pharmacology 75:1, pages 87-95.
Crossref
Crossref
Ning Ding, Lingyan Ping, Lixia Feng, Xiaohui Zheng, Yuqin Song & Jun Zhu. (2014) Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells. Cancer Cell International 14:1.
Crossref
Crossref
Claudia V. Andreu-Vieyra & James R. Berenson. (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Therapeutic Advances in Hematology 5:6, pages 197-210.
Crossref
Crossref
Mark S. Butler, Avril A. B. Robertson & Matthew A. Cooper. (2014) Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31:11, pages 1612-1661.
Crossref
Crossref